Clinical Trials
8 trialsNCT03223103 2025-09-10
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
Albert Einstein College of Medicine
Phase 1 Active not recruiting
NCT01188096 2023-06-12
Poly-ICLC
Wake Forest University Health Sciences
Phase 2 Completed
NCT01810016 2022-10-12
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT02721043 2021-01-11
Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT01079741 2018-02-13
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT01734564 2017-04-11
Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Completed
NCT02661100 2016-12-07
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT00874861 2015-12-08
HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas
University of Pittsburgh
Phase EARLY_PHASE1 Completed